Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Augustine Lawlor | M | 67 |
Replidyne, Inc.
 Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 22 years |
| William Cohn | M | 64 | 9 years | |
| Martha Aronson | F | 56 | 7 years | |
| Stephen Stenbeck | M | 63 | 5 years | |
| Scott Gilbertson | M | - |
TPG Growth LLC
 TPG Growth LLC Investment ManagersFinance TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom. | 17 years |
| Ransom Langford | M | 52 |
TPG Growth LLC
TPG Growth LLC Investment ManagersFinance TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom. | 15 years |
| Patrick McCroskey | M | 61 |
TPG Biotechnology Genpar LP
| 17 years |
| Scott Eaker | M | - |
Prolacta Bioscience, Inc.
 Prolacta Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Prolacta Bioscience, Inc. provides specialty formulations of human milk for the nutritional needs of premature and critically ill infants. Its products include Prolact+ H2MF, Prolact+4, Prolact+6, Prolact+8, Prolact+10 and Neo20. The company was founded by Elena Taggart Medo in1999 and is headquartered in Duarte, CA. | 17 years |
| Alan Kofsky | M | - |
Prolacta Bioscience, Inc.
Prolacta Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Prolacta Bioscience, Inc. provides specialty formulations of human milk for the nutritional needs of premature and critically ill infants. Its products include Prolact+ H2MF, Prolact+4, Prolact+6, Prolact+8, Prolact+10 and Neo20. The company was founded by Elena Taggart Medo in1999 and is headquartered in Duarte, CA. | 15 years |
| Timothy Millikin | M | 41 |
TPG Growth LLC
TPG Growth LLC Investment ManagersFinance TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom. | 17 years |
| Sandra Sedo | F | 60 | 8 years | |
| Michael Stone | M | - |
TPG Growth LLC
TPG Growth LLC Investment ManagersFinance TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom. | 15 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Scott Ward | M | 64 | - | |
| Laurence L. Betterley | M | 70 | 10 years | |
| David L. Martin | M | 59 | 8 years | |
| John Mack | M | 79 |
Credit Suisse First Boston Corp.
| 3 years |
| Nebojsa Janjic | M | 63 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 8 years |
| Erik Paulsen | M | 59 | 4 years | |
| Kelvin Womack | M | 67 | - | |
| Erik M. Glover | M | - |
TPG Growth LLC
TPG Growth LLC Investment ManagersFinance TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom. | - |
| Mark L. Smith | M | 72 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 years |
| Dan Krebs | M | - |
TPG Growth LLC
TPG Growth LLC Investment ManagersFinance TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom. | - |
| Geoff Duyk | M | 64 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 5 years |
| Carla A. Rummo | F | - |
TPG Growth LLC
TPG Growth LLC Investment ManagersFinance TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom. | - |
| Tony James | M | 73 |
Credit Suisse First Boston Corp.
| 2 years |
| Bruce A. Feldman | M | - |
Health Evolution Management Co. LLC
 Health Evolution Management Co. LLC Investment ManagersFinance Health Evolution Management Co. LLC (Health Evolution Management) is a private equity firm founded in 2007 by David J. Brailer. The firm is headquartered in San Francisco, California. | 3 years |
| Kevin Kenny | M | 58 | 7 years | |
| Leslie Trigg | F | 53 | 7 years | |
| Sachin Jain | M | 43 | 1 years | |
| Brent G. Blackey | M | 65 | 12 years | |
| John H. Friedman | M | 71 | 7 years | |
| Alexander Rosenstein | M | 52 | 9 years | |
| Scott A. Bartos | M | 61 | 7 years | |
| Jason A. Leverone | M | 50 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 years |
| Kathleen Kiley Murphy | F | - |
Credit Suisse First Boston Corp.
| 4 years |
| Mark Piegza | M | 56 |
Credit Suisse First Boston Corp.
| 1 years |
| William Tao | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| Andres Roberto Sinclair | M | 63 |
Credit Suisse First Boston Corp.
| - |
| Chris Gilmore | M | - |
Credit Suisse First Boston Corp.
| 5 years |
| Timothy O. McCarthy | M | - |
Credit Suisse First Boston Corp.
| 2 years |
| Stephen E. Stonefield | M | 75 |
Credit Suisse First Boston Corp.
| - |
| Jake Peters | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| Joe Benavides | M | 52 |
Credit Suisse First Boston Corp.
| 3 years |
| Pamela McCormack | F | 53 |
Credit Suisse First Boston Corp.
| 4 years |
| Olivier Sarkozy | M | 54 |
Credit Suisse First Boston Corp.
| - |
| Mark Charles Lamarre | M | - |
Credit Suisse First Boston Corp.
| 4 years |
| David Graber | M | 53 |
Credit Suisse First Boston Corp.
| 4 years |
| John Robert Cavalieri | M | - |
Credit Suisse First Boston Corp.
| - |
| Tarek Ajouz | M | - |
Credit Suisse First Boston Corp.
| 1 years |
| Jon Vanden Heuvel | M | - |
Credit Suisse First Boston Corp.
| 4 years |
| Robert J. Sypher | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| Malcolm Andrew Levine | M | - |
Credit Suisse First Boston Corp.
| 2 years |
| Steven D’Agostino | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| Randolph Simpson | M | 55 |
Credit Suisse First Boston Corp.
| 2 years |
| Steven Lloyd Kantor | M | - |
Credit Suisse First Boston Corp.
| - |
| W. Bryan Kimzey | M | - |
Credit Suisse First Boston Corp.
| 6 years |
| Robert Perelman | M | 61 |
Credit Suisse First Boston Corp.
| 5 years |
| Brian S. Berkin | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| Keith McCormack | M | - |
Credit Suisse First Boston Corp.
| - |
| Ho Ping Lin | M | 52 |
Credit Suisse First Boston Corp.
| 4 years |
| Graham Morgan McPhail | M | 49 |
Credit Suisse First Boston Corp.
| 4 years |
| Badal Pandhi | M | - |
Credit Suisse First Boston Corp.
| 2 years |
| George A. Schreiber | M | 75 |
Credit Suisse First Boston Corp.
| 5 years |
| Steven M. Wolf | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| Jonathan W. Chen | M | 49 |
Credit Suisse First Boston Corp.
| 5 years |
| Mark A. Adley | M | 64 |
Credit Suisse First Boston Corp.
| 5 years |
| Lodewijk J. R. de Vink | M | 78 |
Credit Suisse First Boston Corp.
| 2 years |
| Stephen R. Volk | M | 87 |
Credit Suisse First Boston Corp.
| 7 years |
| Lester Brafman | M | 61 |
Credit Suisse First Boston Corp.
| 6 years |
| Richard Harold Bott | M | 77 |
Credit Suisse First Boston Corp.
| 21 years |
| Jonathan Plutzik | M | 69 |
Credit Suisse First Boston Corp.
| 24 years |
| Richard J. Char | M | 64 |
Credit Suisse First Boston Corp.
| 3 years |
| David O'Leary | M | 77 |
Credit Suisse First Boston Corp.
| 15 years |
| Matthew K. Behrent | M | 54 |
Credit Suisse First Boston Corp.
| 3 years |
| Samuel Liss | M | 67 |
Credit Suisse First Boston Corp.
| 7 years |
| Frank S. Plimpton | M | 68 |
Credit Suisse First Boston Corp.
| 4 years |
| Timothy J. Ng | M | 59 |
Credit Suisse First Boston Corp.
| 3 years |
| Ed Garden | M | 62 |
Credit Suisse First Boston Corp.
| 4 years |
| Kelly K. Masuda | M | 56 |
Credit Suisse First Boston Corp.
| 2 years |
| Anthony Chidoni | M | 72 |
Credit Suisse First Boston Corp.
| 14 years |
| John Cavalier | M | 72 |
Credit Suisse First Boston Corp.
| 8 years |
| Russ Ray | M | 77 |
Credit Suisse First Boston Corp.
| 3 years |
| John Boniface Maier | M | 62 |
Credit Suisse First Boston Corp.
| - |
| Matthew C. Duda | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| Chris Ricciardi | M | 54 |
Credit Suisse First Boston Corp.
| 3 years |
| Paras Mehta | M | - |
Credit Suisse First Boston Corp.
| 4 years |
| Bryan Lloyd | M | - |
Credit Suisse First Boston Corp.
| 3 years |
| James L. Alexandre | M | 67 |
Credit Suisse First Boston Corp.
| 2 years |
| Paul D'Addario | M | 71 |
Credit Suisse First Boston Corp.
| 4 years |
| Todd Morgan | M | - |
Credit Suisse First Boston Corp.
| 1 years |
| Fayez Muhtadie | M | 46 |
Credit Suisse First Boston Corp.
| 2 years |
| J. Kent Sweezey | M | 71 |
Credit Suisse First Boston Corp.
| 18 years |
| Dave Zion | M | - |
Credit Suisse First Boston Corp.
| 11 years |
| Robert Rutschow | M | - |
Credit Suisse First Boston Corp.
| 2 years |
| Frank H. Pinkerton | M | - |
Credit Suisse First Boston Corp.
| 2 years |
| Bob Kricheff | M | - |
Credit Suisse First Boston Corp.
| 13 years |
| David Silver | M | - |
Credit Suisse First Boston Corp.
| 6 years |
| John Frederick Nelson | M | 76 |
Credit Suisse First Boston Corp.
| - |
| David Matlin | M | 62 |
Credit Suisse First Boston Corp.
| 7 years |
| Frederick M. R. Smith | M | 82 |
Credit Suisse First Boston Corp.
| 35 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Edward Brown
- Personal Network
